SARS-CoV-2 (COVID-19) Spike 156-157EFdel Peptide (Delta Variant)

SARS-CoV-2 delta variant, a variant of concern (VOC), known as B.1.617.2, was detected in India in October of 2020. However, it rapidly spread all over of the world and now it is the dominant variant in the world, which account for more than 99% of the cases. This variant carries at least 13 mutations in spike protein across the sub lineages, including L452R, D614G, P681R and K417N, which can increase the affinity to the human ACE2 receptor. Enhanced transmission of the Delta variant was observed globally, which is at least 2.5 times more contagious as the other variants. The Delta variant affects the effectiveness of COVID19 vaccine and is resistant to neutralization to some extent.

SARS-CoV-2 (COVID-19) Spike 156-157EFdel Peptide (Delta Variant) is used for blocking the activity of theSARS-CoV-2 (COVID-19) Spike 156-157EFdel Antibody (Delta Variant)